Antibody to begin Phase II clinical study at the University of Pittsburgh Cancer Institute Melanoma and Skin Cancer Program (UPCI trial 07-023) […]
GREENWICH, Conn.–(BUSINESS WIRE)–Life Science Pharmaceuticals, Inc. announced today that it has entered into a license agreement with Abbott to develop Antibody 806, […]
Darien, Conn., Dec 14, 2010 —Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase […]
About ABT-414 ABT-414 is an anti-EGFR (epidermal growth factor receptor) monoclonal antibody drug conjugate (ADC). As an ADC, ABT-414 is designed to […]
Mr. Fiore co-founded Life Science Group in 1997. His business interests include essentially all facets of biotechnology management, business development, scientific discovery […]
Mr. Van Steen co-founded Life Science Group (LSG) in 1997, a boutique investment banking firm focused exclusively on the life science industry. […]
Dr. Pramod K. Srivastava, an accomplished leader in basic and translational research, is the director of the Carole and Ray Neag Comprehensive […]
Lloyd J. Old, M.D., is the Director of the Ludwig Institute for Cancer Research (LICR) New York Branch at Memorial Sloan-Kettering Cancer […]